CleanCore Solutions, Inc.

ZONE
About the company

CleanCore Solutions, Inc. engages in development and production of cleaning products that produce pure aqueous ozone for professional, industrial, and home use.

Country: United StatesPrice: $3.60Market Cap: $30.6M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

1 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Graham, Buffett, Lynch +1 more object

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILPASSFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-08-22

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-08-22

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2025-08-22

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-08-22

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-08-22

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-09-28

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-09-28

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.02, IC: -353.9x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.02
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities21.24
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.02
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.02
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDA
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.02
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0155; #702/4210 (top 16.7%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Profitability0% pass✓ 1✗ 34▾

    No clean pass — all 16 investors flag at least one profitability criterion

    Positive EPS (10 years)0/5 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/5 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-327.0%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-6.6M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-338.1%
    ✗Lynch> 15%
    EBIT / Enterprise Value-21.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-21.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-79.63%
    ✗PiotroskiROA > 0
    ROA Change YoY-79.63% -> -79.63% (delta: +0.00%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-27.61%, ROA=-79.63%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY47.6% -> 47.6%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-338.1%
    ✗Dreman> 12%
    Margin of SafetyP/B=27.4x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-327.0% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/3 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-1704.3%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-338.1%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-121.3% (2023) -> -308.1% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 49.6% -> 47.6%, operating margin -121.3% -> -308.1%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-569.27%; #5950/6340 (top 93.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+2.45%; #3242/3702 (top 87.6%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-338.09%; #5010/5226 (top 95.9%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.2316; #4371/5884 (top 74.3%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation0% pass✓ 2✗ 26▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio27.4x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-21.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-21.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share27.4x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-16.3%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-7.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=27.4x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low2812% of trailing low ($0.13)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-569.27%; #5950/6340 (top 93.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+1.6838; #797/6449 (top 12.4%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share27.44x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.1112; #4274/5247 (top 81.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-7.75%; #3138/4519 (top 69.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+990.91%; #40/6202 (top 0.6%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy$-6.6M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-2.4M
    ✗LynchPositive and growing
    Operating Cash Flow$-2.3M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-27.61%, ROA=-79.63%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-7.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/3 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-5.9%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/3 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-2.4M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-7.75%; #3138/4519 (top 69.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 2✗ 11▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -32.5% vs Rev: 64.2%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/3 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth14.6%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 49.6% -> 47.6%, operating margin -121.3% -> -308.1%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Verdicts7% pass✓ 1✗ 14▾

    Split decision: 14 FAIL · 1 PASS · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (1/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (2/11)✓MungerPASS (2/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #1451/2370 (Top 61.2%))✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 2✗ 9▾

    6 of 8 flag ZONE's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio21.24
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-73.3%
    ✗Buffett> 10%
    ROIC - WACC-83.3%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
    ✗Greenblatt> 25%
    Current Ratio Change YoY1.34 -> 1.34
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.24x -> 0.24x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities21.24
    ✓Dreman> 1.5
    Return on Invested Capital-87.6%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-24.6%; FY2024: ROIC=-83.6%; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/2 years above 12% (latest -83.6%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Consumer Goods
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($30.6M)
Revenue: $2.1M+0.0% YoY
Net Income: $6.7M+0.0% YoY

Financial Snapshot

Operating Margin-308.1%
Return on Equity-459.9%
Debt / Equity--
Current Ratio1.34

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-06-30

2025-07-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, interest expense.

Q4 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow, depreciation amortization.

Q3 FY 2026

2026-01-01 – 2026-03-31

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2025-10-01 – 2025-12-31

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2025-07-01 – 2025-09-30

Sources
FY 2025
Sources
  • 10-K · 2025-08-22
FY 2024
Sources
  • 10-K · 2025-08-22
FY 2023
Sources
  • 10-K · 2024-09-20
FY 2022
Sources
  • 10-K · 2024-09-20
FY 2021
Sources
  • 10-K · 2024-09-20
Market Cap$30.6Mcurrent--------$4.0Mest.$7.9Mest.------
Revenue$3.4M↑64%$885.9K↓1%$543.7K↓3%$1.1M↑315%$904.7K↑148%$2.1M$2.1M↑29%$1.6M----
Operating Income-$58.0M↓808%-$16.9M↓333%-$12.2M↓1601%-$20.7M↓2049%-$8.2M↓908%-$6.4M-$6.4M↓228%-$1.9M----
Net Income-$174.2M↓2483%-$25.6M↓529%-$30.8M↓3706%-$104.4M↓10284%-$13.4M↓1461%-$6.7M-$6.7M↓195%-$2.3M----
EPS (Diluted)----$-0.14$-0.51$-0.49----------
Gross Margin37.8%↓21%49.8%↑4%-77.1%↓238%68.1%↑182%59.3%↑17%47.6%47.6%↓4%49.6%——
Operating Margin-1704.3%↓453%-1902.6%↓337%-2242.2%↓1645%-1938.3%↓417%-910.5%↓307%-308.1%-308.1%↓154%-121.3%——
ROE-338.1%↑26%————-459.9%-459.9%↓653%-61.1%——
Total Debt$800.0K↓82%$800.0K↓82%$800.0K↓64%$800.0K↓64%$800.0K↓68%--$4.6M↑81%$2.5M↓16%$3.0M--
Shareholders' Equity$51.5M↑3414%$51.5M↑3414%$66.8M↑3959%$93.8M↑4151%$172.5M↑5532%$1.5M$1.5M↓61%$3.7M↑114%$1.7M↑129%-$6.0M
Current Ratio21.24↑1484%21.24↑1484%2.94↑255%1.47↑38%1.33↓18%1.341.34↓37%2.13↑385%0.44—
Debt / Equity0.02↓100%0.02↓100%0.01↓99%0.01↓99%0.00↓99%—3.12↑362%0.67↓61%1.71—
Operating Cash Flow-$18.2M↓677%-$3.3M↓3130%-$7.6M↓1237%-$3.4M↓291%-$3.8M↓375%-$2.3M-$2.3M↓51%-$1.5M----
Free Cash Flow-----$7.7M↓1219%-$3.4M↓290%-$3.8M↓372%-$2.4M-$2.4M↓52%-$1.6M----

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Consumer Goods

ZONE vs Peers — Financial Grading

Revenue$2.1MBottom 25%
Net Income$6.7MBottom 25%
ROE-459.9%Bottom 25%
D/E—
Op. Margin-308.1%Bottom 25%
Curr. Ratio1.34Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
UNILEVER PLCUL$142.6B$66.21$59.3B$11.1B61.0%1.6817.9%0.792/94/94/71/3F-Score 86/11
ECOLAB INC.ECL$86.7B$309.27$16.1B$2.1B21.2%0.8417.0%1.083/95/93/71/3F-Score 65/11
COLGATE PALMOLIVE COCL$79.2B$99.67$20.4B$2.1B3948.1%147.8916.2%0.832/95/93/71/3F-Score 53/11
ESTEE LAUDER COMPANIES INCEL$40.5B$111.75$14.3B$1.1B-29.3%1.89-5.5%1.302/94/92/70/3F-Score 61/11
CHURCH & DWIGHT CO INC /DE/CHD$26.7B$113.00$6.2B$736.8M18.4%0.5517.4%1.073/97/93/71/3F-Score 74/11
CANON INCCAJPY$25.2B$30.28——————3/91/91/71/3F-Score 75/11
SOMNIGROUP INTERNATIONAL INC.SGI$14.0B$60.76$7.5B$384.1M12.4%1.5110.1%0.831/95/92/71/3F-Score 52/11
INTERPARFUMS INCIPAR$4.3B$133.37$1.5B$168.4M19.1%0.2018.2%2.994/95/96/71/3F-Score 57/11